Polypid Ltd
Research Polypid Ltd (PYPD) on Bullrun: market cap USD 101.97M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPYPD
- ExchangeNASDAQ
- CountryIsrael
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 101.97M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 7.85M
Valuation Snapshot
latest market cap is USD 101.97M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 34.17M | -USD 28.09M | n/a | 2.09 | USD 6.40M | USD 988.00K | USD 10.97M |
| FY2024 | USD 0 | -USD 29.02M | -USD 22.04M | n/a | 4.91 | USD 15.64M | USD 7.42M | USD 7.68M |
| FY2023 | USD 0 | -USD 23.87M | -USD 17.43M | n/a | 16.93 | USD 5.31M | USD 10.38M | -USD 2.10M |
| FY2022 | USD 0 | -USD 39.56M | -USD 36.08M | n/a | 61.09 | USD 8.55M | USD 11.60M | USD 5.83M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 101.97M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 79.01M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 30.98M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.28M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 13.72M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 107.66M | n/a | n/a | n/a |
About Polypid Ltd
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Polypid Ltd's market cap?
Polypid Ltd's market capitalization is USD 101.97M.
What does Polypid Ltd do?
PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer.